drugset / Trial / NCT05162196
The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, multicenter, open-label study to observe the efficacy and safety of combination with radiotherapy, niraparib and toripalimab in patients With recurrent small cell lung cancer(SCLC).
Timeline
- Start
- 2022-06
- Primary completion
- 2024-06
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niraparib | Small molecule | 200 mg | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |